Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J8560 Etoposide Toposar 50 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins Yes 1986 Jan 1, 1995 In Use
J9200 Floxuridine Floxuridine 500 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1970 Jan 1, 1984 In Use
NA Fluorouracil Carac, Efudex topical, varies Chemotherapy Antimetabolite Pyrimidine Analog No 1970 In Use
NA Dasatinib Sprycel 140 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9074 Cyclophosphamide (sandoz) Cyclophosphamide (sandoz) 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2014 Apr 17, 2024 In Use
J0881 Darbepoetin alfa Aranesp 1 mcg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2001 Jan 1, 2006 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
J9196 Gemcitabine HCl (Accord) Gemcitabine 200MG Chemotherapy Antimetabolite Pyrimidine Analog No 2011 Mar 17, 2023 In Use
J8600 Melphalan Melphalan, Alkeran 2 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1992 Jan 1, 1995 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
J9263 Oxaliplatin Eloxatin 0.5 mg Chemotherapy Alkylating Agent Platinum Compound No 2002 Jan 1, 2004 In Use
NA Dasatinib Sprycel 80 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J1675 Histrelin Acetate Supprelin LA, Vantas 10 mcg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2006 In Use
C9024 (Daunorubicin AND Cytarabine) Liposome Vyxeos 1mg/2.27mg Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog No 2017 In Use
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan 1, 2016 In Use
N/A Relacorilant Lifyorli 25mg, 100mg Chemotherapy Glucocorticoid Receptor (GR) Antagonist Yes 2026 In Use
N/A Vepdegestrant Veppanu 100mg, 200mg Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Yes 2026 In Use
N/A Zidesamtinib Jideytro 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Yes 2026 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.